Seven Eight Capital’s Vir Biotechnology VIR Stock Holding History

Seven Eight Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,808	Closed	-$304K	–	641
2022 Q1	$304K	Buy	+11,808	New	+$350K	0.04%	405
2021 Q4	–	Sell	-11,957	Closed	-$520K	–	690
2021 Q3	$520K	Buy	+11,957	New	+$518K	0.05%	432
2021 Q2	–	Sell	-26,894	Closed	-$720K	–	715
2021 Q1	$720K	Hold	26,894	–	–	0.17%	210
2020 Q4	$720K	Buy	+26,894	New	+$874K	0.16%	213

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Seven Eight Capital's VIR Position: Q2 2022 in Review

Seven Eight Capital sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 11,808 shares — an estimated $304K sold.

Seven Eight Capital first reported a position in VIR in Q4 2020 and held it in 4 quarters. The position peaked at $720K in Q1 2021. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

Seven Eight Capital reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
Seven Eight Capital sold 11,808 Vir Biotechnology shares in Q2 2022, an estimated $304K.
Seven Eight Capital first reported a position in Vir Biotechnology in Q4 2020 and held it in 4 quarters.
Seven Eight Capital's Vir Biotechnology position peaked at $720K in Q1 2021.
212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Seven Eight Capital's 13F filing for Q2 2022, filed 4 Aug 2022.